About Unichem Laboratories Limited

Unichem Laboratories Limited is a public company domiciled in India, engaged in the manufacture and marketing of pharmaceutical formulations and Active Pharmaceutical Ingredients (APIs) for regulated and emerging markets worldwide. The Company operates three finished formulation plants (Ghaziabad, Goa, and Baddi), three API facilities (Roha, Pithampur, and Kolhapur), and a dedicated R&D Centre in Goa supported by over 300 scientists and state-of-the-art laboratories for various dosage forms including tablets, capsules, liquid orals, creams, ointments, and injectables. Over the years, Unichem has filed 84 Abbreviated New Drug Applications (ANDAs) with 71 approvals, 79 US Drug Master Files (USDMFs), 30 CEPs, and other filings across key markets, reflecting its expertise in generics and complex products.

The company exports to several developed and developing countries, including the U.S., Europe, Ireland, South Africa, and Brazil. FY 2024–25 was the first full year after Unichem became part of the Ipca group, marking a key milestone. Operationally, it reported a 52% increase in formulation output year-on-year, driven by automation, process improvements, and capacity expansion, including an 81% increase in Pithampur’s installed capacity. As of the reporting year, Unichem had six subsidiaries, with the Ireland subsidiary’s full ownership transferred to Ipca Laboratories Limited post-March 31, 2025.

Key Milestones of Unichem Laboratories Limited

• Completion of integration into the Ipca group in FY 2024–25.
• 52% increase in formulation output due to technological and capacity enhancements.
• Substantial expansion of manufacturing capacity at the Pithampur facility by 81%.
• Multiple ANDA approvals and new product launches in the U.S. and South Africa.

Unichem Laboratories Limited Business Segment

The company focuses on manufacturing and marketing pharmaceutical formulations (branded generics and generics) and APIs for global regulated and emerging markets.

Exports constituted approximately 98.02% of consolidated sales revenue, with Unichem USA contributing 64% of total sales revenue. The company operates in regulated and emerging pharmaceutical markets worldwide.

Unichem Laboratories Limited Key Management

• Dr. Prakash A. Mody – Chairman, Non-Executive & Non-Independent
• Pabitrakumar Bhattacharyya – Managing Director
• Sanjay Jain – Chief Financial Officer
• Pradeep Bhandari – Head – Legal & Company Secretary

Latest Updates on Unichem Laboratories Limited

• Underwent USFDA and EU-GMP audits with certifications and documented VAI status.
• Received 4 ANDA approvals, launched multiple products, and filed new ANDAs, USDMFs, CEPs, and CADIFA filings in FY 2024-25.
• Transferred 100% stake in Ireland subsidiary to Ipca Laboratories Limited; decided to close UK leased facility consolidating production in India.
• ICRA upgraded the company’s long-term credit rating to A+ (Stable).
• Capital expenditure of Rs 126.31 crore spent on capacity expansion and operational improvements.